Shift in brain metabolism in late onset Alzheimer’s disease: Implications for biomarkers and therapeutic interventions
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Alzheimer’s is a neurodegenerative disease with a complex and progressive pathological phenotype characterized first by hypometabolism and impaired mitochondrial bioenergetics followed by pathological burden. Increasing evidence indicates an antecedent and potentially causal role of mitochondrial bioenergetic deficits and brain hypometabolism coupled with increased mitochondrial oxidative stress in AD pathogenesis. Compromised mitochondrial bioenergetics lead to over-production and mitochondrial accumulation of β-amyloid coupled with oxidative stress to cause a shift in brain metabolic profile from glucose-driven bioenergetics towards a compensatory, but less efficient, ketogenic pathway. We propose that the compensatory shift from a primarily aerobic glycolysis pathway to a ketogenic/fatty acid β-oxidation pathway eventually leads to white matter degeneration. The essential role of mitochondrial bioenergetics and the unique trajectory of compensatory metabolic adaptations in brain enable a bioenergetic-centric strategy for development of biomarkers to detect the bioenergetic shift in brain to enable early identification of people at risk for developing AD. From a therapeutic perspective, this unique trajectory of alterations in brain metabolic capacity enable disease-stage specific strategies targeting brain metabolism for disease prevention and treatment. A combination of nutraceutical and pharmaceutical intervention that enhances glucose-driven metabolic activity and potentiates mitochondrial bioenergetic function could prevent the antecedent decline in brain glucose metabolism, promote healthy aging and prevent AD. Alternatively, during the prodromal incipient phase of AD, sustained activation of ketogenic metabolic pathways coupled with supplement of the alternative fuel source, ketone bodies, can sustain mitochondrial bioenergetic function to prevent or delay further progression of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“…the deposition of Ab initiates a cascade of events, including the formation of NFTs, prolonged inflammatory responses, increased oxidative stress and mitochondrial dysfunction, which eventually lead to cell death and dementia (Armstrong, 2011; Hardy, 2006; Hardy and Higgins, 1992; Sommer, 2002).”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Recently the clinical phases of AD have been expanded to include presymptomatic AD, during which time an individual appears cognitively normal but is beginning to exhibit some of the pathological changes of AD (Sperling et al., 2011).”
BackgroundMitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“As the major source for cellular reactive oxygen species, mitochondria generate free radicals (superoxide anion, O2 ) and hydrogen peroxide (H2O2) as by-products of oxidative phosphorylation (Dumont et al., 2010; Lin and Beal, 2006).”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 5×
“CSF levels of both total tau and p-tau are increased, likely due to degenerating neurons releasing these proteins into the CSF (Jack et al., 2010).”
BackgroundInfluentialOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 2×
“Interestingly, an increase in oxidative stress has been demonstrated to increase b-amyloid production in vitro and in vivo (Li et al., 2004; Moreira et al., 2007; Nunomura et al., 2001).”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 3×
“All rights reserved. acology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los 436; fax: +1 323 442 1470. exponentially with age in people 65 or older (Hansson et al., 2006).”
BackgroundInfluentialABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104 · cited 4×
“Mitochondrial dysfunction results in a series of changes that contribute to Aβ accumulation in mitochondria, including impaired oxidative phosphorylation, uncoupled electron transport chain, compromised ATP synthase, and COX inhibition (Manczak et al., 2006; Readnower et al., 2011; Young and Bennett, 2010).”
BackgroundInfluential[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 2×
“…phase was particularly important for explaining why some individuals have no cognitive deficits but, upon autopsy, amyloid plaques and neurofibrillary tangles are present in the brain (De Meyer et al., 2010; Jack et al., 2008; Knopman et al., 2003; Mintun et al., 2006; Price and Morris, 1999).”
BackgroundFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 5×
“…antecedent abnormality in cerebral glucose utilization decades prior to the onset of AD, particularly in the hippocampal and entorhinal cortical regions (de Leon et al., 2001; Ishii et al., 1997; Mosconi et al., 2008, 2009a; Reiman et al., 2004; Rosenbloom et al., 2011; Spulber et al., 2008).”
BackgroundInfluential
Cited by
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Self-citationPerimenopause as a neurological transition state
Brinton, R. D., Yao, J., Yin, F., Mack, W. J., & Cadenas, E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.82 · Cited by 612
Self-citationEstrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
Self-citationTrushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438
Ketogenic Diet in Alzheimer’s Disease
Rusek, M., Pluta, R., Ułamek-Kozioł, M., & Czuczwar, S. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163892 · Cited by 319
Minireview: translational animal models of human menopause: challenges and emerging opportunities
Diaz Brinton, R. (2012) · Endocrinology · doi:10.1210/en.2012-1340 · Cited by 272
Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier
Vacanti, N. M., Divakaruni, A. S., Green, C. R., Parker, S. J., Henry, R. R., Ciaraldi, T. P., Murphy, A. N., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.024 · Cited by 277
“…diabetes and obesity (DeFronzo and Tripathy, 2009; Sugden et al., 2009), mitochondrial disorders (Kerr, 2013), cardiac failure (Fillmore and Lopaschuk, 2013), neurode- Mole generative disorders (Cunnane et al., 2011; Yao et al., 2011), and cancer (Currie et al., 2013; Tennant et al., 2010).”
BackgroundInsulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Ding, F., Yao, J., Rettberg, J. R., Chen, S., & Brinton, R. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079977 · Cited by 262
Self-citationMetabolic and inflammatory adaptation of reactive astrocytes: role of PPARs
Iglesias, J., Morales, L., & Barreto, G. E. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9833-2 · Cited by 137
Yin, F., Yao, J., Sancheti, H., Feng, T., Melcangi, R. C., Morgan, T. E., Finch, C. E., Pike, C. J., Mack, W. J., Cadenas, E., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.013 · Cited by 136
Self-citationPeng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58
“These tend to focus on age-related faulty mitochondrial bioenergetics, accumulation of A within mitochondria coupled with oxidative stress, and other such factors [224], all driving a shift from glucose-driven bioenergetics towards a ketogenic/ -oxidation pathway.”
BackgroundMitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential
Mi, Y., Qi, G., Brinton, R. D., & Yin, F. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8070 · Cited by 43
“Such a switch was consistently seen in our previous studies, in which chronological aging, female endocrine aging, and AD pathology all led to glucose hypometabolism and elevated utilization of ketone bodies (40, 90, 183, 185, 191).”
BackgroundSelf-citationWang, Y., Shang, Y., Mishra, A., Bacon, E., Yin, F., & Brinton, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65402-5 · Cited by 42
Self-citationHu, L.-T., Zhu, B.-L., Lai, Y.-J., Long, Y., Zha, J.-S., Hu, X.-T., Zhang, J. H., & Chen, G.-J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.069 · Cited by 35
Carroll, C. M., & Macauley, S. L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00258 · Cited by 32
“Aerobic glycolysis is an emerging biomarker of network vulnerability in AD where brain regions prone to Aβ deposition utilize glucose beyond what is necessary for energy production, even though sufficient concentrations of oxygen exist for oxidative phosphorylation and ATP generation (Vlassenko et al., 2010, 2018; Yao…”
BackgroundSáez-Orellana, F., Leroy, T., Ribeiro, F., Kreis, A., Leroy, K., Lalloyer, F., Baugé, E., Staels, B., Duyckaerts, C., Brion, J.-P., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150099 · Cited by 29
“18 in brain metabolism from glucose-driven energy supp ly to a ketogenic/FA oxidation pathways 344 is reported in LOAD (58), this shift could depend o n the level of APP expression.”
Background
Metadata
- Authors
- Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 32
- Issue
- 4-6
- Pages
- 247-257
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W2129437576
- Cited by
- 123
- References
- 49
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.